Home > News > 75/Sex-specific differences in survival and heart failure hospitalisation after cardiac resynchronisation therapy with or without defibrillation
Arrhythmia
Read Time: < 1 min

75/Sex-specific differences in survival and heart failure hospitalisation after cardiac resynchronisation therapy with or without defibrillation

Published Online: October 3rd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr75
Authors: F Leyva (Presenting Author) - Aston University, Birmingham, UK; T Qiu - Aston University, Birmingham, UK; A Zegard - Aston University, Birmingham, UK; O Okafor - Aston University, Birmingham, UK; D McNulty - Queen Elizabeth Hospital, Birmingham, UK; F Evison - Queen Elizabeth Hospital, Birmingham, UK; Ray - NHS Digital and Farr Institute, London, UK; M Gasparini - Electrophysiology and Pacing Unit, Humanitas Research Hospital IRCCS, Milan, Italy
Quick Links:
Article
Article Information
Article:

Background: Women are underrepresented in cardiac resynchronisation therapy (CRT) trials. Some studies suggest that women fare better than men after CRT.

Objectives: To explore clinical outcomes in women and men undergoing CRT-defibrillation (CRT-D) or -pacing (CRT-P) in real-world clinical practice.

Methods: A national database (Hospital Episode Statistics for England) was used to quantify clinical outcomes in 43,730 patients (women: 10,890 [24.9%], men: 32,840 [75.1%]) undergoing CRT over 7.6 years, (median follow-up 2.2 yrs, interquartile range, 1–4 yrs).

Results: In analysis of the total population, the primary endpoint of total mortality (adjusted hazard ratio [aHR]: 0.73, 95% confidence interval [CI] 0.69–0.76) and the secondary endpoint of total mortality or HF hospitalisation (aHR: 0.79, 95% CI 0.75–0.82) were lower in women, independent of known confounders. Total mortality (aHR: 0.73, 95% CI 0.70–0.76) and total mortality or HF hospitalisation (aHR: 0.79, 95% CI 0.75–0.82) were lower for CRT-D than for CRT-P. In analyses of patients with (aHR:0.89, 95% CI 0.80–0.98) or without (aHR:0.70, 95%CI 0.66–0.73) a myocardial infarction, women had a lower total mortality. In sex-specific analyses, total mortality was lower after CRT-D in women (aHR: 0.83, p=0.013) and men (aHR: 0.69, p<0.001).

 

Conclusions: Compared to men, women lived longer and were less likely to be hospitalised for HF after CRT. In both sexes, CRT-D was superior to CRT-P with respect to survival and HF hospitalisation. The longest survival after CRT was observed in women without a history of MI.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72